- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01185704
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART) (ATTAC-PCO)
A Phase IIIb Randomized Open-label Study to Compare the Estradiol Level on the Releasing Day in Two Regimen of Cetrotide® 0.25 mg Used From Day 1 or From Day 7 of the Menstrual Cycle (Day 0 or Day 6 of Stimulation) in Polycystic Ovarian (PCO) Women in ART (IVF/ICSI).
Study Overview
Status
Conditions
Detailed Description
Polycystic ovarian syndrome population is an androgenic syndrome characterized by a wide spectrum of clinical manifestations such as obesity, hirsutism, insulin resistance, diabetes and presence of specific ultrasonic features.
Cetrotide®, cetrorelix acetate, is an antagonist of luteinizing-hormone-releasing hormone (LHRH). Cetrotide® is registered in 70 countries (including France) for the prevention of premature ovulation in subjects undergoing a controlled ovarian stimulation, followed by oocyte pick-up and ARTs. Ovitrelle®, active ingredient human chorionic-gonadotropin alfa, is administered to trigger final follicular maturation and luteinization after stimulation of follicular growth.
OBJECTIVES
Primary objective:
- To compare the hormonal level of plasmatic estradiol on the releasing day (day of r-hCG administration) induced by Cetrotide® 0.25 mg/day started on Day 1 (Group A: Day 1) or on Day 7 (Group B: Day 7) of the menstrual cycle (Day 0 (S0) or Day 6 (S6) of stimulation) in PCO subjects undergoing IVF/ICSI procedures.
Secondary objectives:
- To compare the hormonal changes during the stimulation induced by Cetrotide® in A and B Groups
- To assess by ultrasound scans (US) the follicular development induced by Cetrotide® in A and B Groups
- To assess biological and clinical outcomes induced by Cetrotide® in A and B Groups
- To monitor safety of Cetrotide in A and B Groups
The trial will be conducted on an outpatient basis. Once each subject has met all eligibility criteria, they will be randomly assigned in one of the two treatment groups.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Toulouse, France
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female subjects with PCO or Polycystic ovary syndrome (PCOS) according to the revised 2003 Rotterdam Consensus
- Female subjects suitable for IVF/ICSI, undergoing first or second attempt
- 18-35 years old, Body Mass Index (BMI) less than or equal to 32, non-smoking at least from Visit 0 (V0)
- Normal FSH value (less than 10 international unit per liter [IU/L]) on Day 3 of spontaneous cycle within 12 months prior to the trial
- Anti Mullerian Hormone (AMH) value (greater than 1.5 nanogram per milliliter [ng/mL]) of a spontaneous cycle within 12 months prior to the trial or at least at V0
- No history of active genito-urinary infection
- Normal thyroid function (or adequate substitution for at least 3 months)
- Negative cervical papanicolaou test within the last 12 months prior to study entry
- No gonadotropins, for at least one month prior to the trial
- No metformin therapy for at least one month prior to Visit 1 (V1)
- Subject who is able to participate in the trial and has provided written, informed consent.
Exclusion Criteria:
- Ongoing pregnancy, any pregnancy within 3 months prior to study entry, or any contraindication to pregnancy or carrying pregnancy to term
- Drilling 3 months prior to V0
- Uterine malformation, diethylstilbestrol syndrome, synechia
- Female subjects with World Health Organization (WHO) Type I or III anovulation
- Female subjects with hyperprolactinemia
- Female subjects with more than 2 recurrent miscarriages (early or late, and for any reasons)
- Known infection with Human Immunodeficiency Virus (HIV), Hepatitis B or C virus, for subject or partner
- Abnormal gynecological bleeding of undetermined origin
- History of major thromboembolic disease
- Endometriosis (Grade III or IV)
- Presence or history of malignant tumors and related treatment
- Known case of tumors of the hypothalamus or pituitary gland
- Clinically significant systemic disease or clinically significant abnormal hematology, chemistry, or urinalysis results at screening
- Known allergic reaction or hypersensitivity to Cetrotide® or Ovitrelle®
- Any active substance abuse or history of drug, medication or alcohol abuse in the past 5 years
- Participation in another clinical trial within 3 months prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Day 1 protocol
|
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
Other Names:
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
Other Names:
The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
Other Names:
Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
|
Experimental: Day 7 protocol
|
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
Other Names:
Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
Other Names:
The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
Other Names:
Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Estradiol (E2) Levels on r-hCG Day
Time Frame: r-hCG day (end of stimulation cycle [approximately 15 days])
|
r-hCG day (end of stimulation cycle [approximately 15 days])
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Levels
Time Frame: Day 1
|
Day 1
|
|
Serum Estradiol (E2) Levels
Time Frame: Day 1
|
Day 1
|
|
Serum Progesterone (P4) Levels
Time Frame: Day 1
|
Day 1
|
|
Anti Mullerian Hormone (AMH) Levels
Time Frame: Day 0
|
Day 0
|
|
Number of Follicles Greater Than or Equal (>=) to 17 mm (For Day 1 Protocol) or 19 mm (For Day 7 Protocol) on r-hCG Day
Time Frame: r-hCG day (end of stimulation cycle [approximately 15 days])
|
r-hCG day (end of stimulation cycle [approximately 15 days])
|
|
Number and Quality of Oocytes Retrieved
Time Frame: Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Oocyte retrieval is a technique used in in-vitro fertilization (IVF) in order to remove oocytes from the ovary of the female participant, enabling fertilization outside the body.
Oocytes were classified into 4 different categories based on their quality: mature, fractured, immature and inseminated oocytes.
|
Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Total Dose of Recombinant Human Follicle Stimulating Hormone (r-hFSH)
Time Frame: Day 1 up to r-hCG day (end of stimulation cycle [approximately 15 days])
|
Day 1 up to r-hCG day (end of stimulation cycle [approximately 15 days])
|
|
Percentage of Fertilized Oocytes Retrieved
Time Frame: Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Oocytes were fertilized using Intra-cytoplasmic Sperm Injection (ICSI) technique which is an IVF procedure in which a single sperm is injected directly into an egg under a microscope.
|
Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Number of Embryos
Time Frame: Day 2-3 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Embryo is defined as the product of the zygote, two or three days after fertilization of the oocytes.
|
Day 2-3 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Number of Blastocysts
Time Frame: Day 5-6 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Blastocyst is an embryo, five or six days after fertilization, with an inner cell mass, outer layer of trophectoderm and a fluid-filled blastocoele cavity.
|
Day 5-6 post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Number of Transferred Embryos
Time Frame: Day 2-3 post Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Embryo transfer is the procedure in which one or more embryos are placed in the uterus.
|
Day 2-3 post Oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Implantation Rate
Time Frame: 5 weeks post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Implantation rate per reporting group was measured as the number of gestational sacs observed, divided by the number of embryos transferred multiplied by 100.
|
5 weeks post oocytes retrieval day (36 +/- 2 hours post r-hCG day [end of stimulation cycle {approximately 15 days}])
|
Percentage of Participants With Clinical Pregnancy
Time Frame: 10 weeks post r-hCG day (end of stimulation cycle [approximately 15 days])
|
Clinical pregnancy was defined as pregnancy diagnosed by ultrasonographic visualization of one or more gestational sacs or definitive clinical signs of pregnancy.
It excludes ectopic pregnancy.
|
10 weeks post r-hCG day (end of stimulation cycle [approximately 15 days])
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Day 1 up to end of study (15 days post last administration of study drug)
|
An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerges or worsens relative to baseline during a clinical study with an Investigational Medicinal Product (IMP), regardless of causal relationship and even if no IMP has been administered.
A Serious Adverse Event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect.
To avoid the participant/event combination double-count AEs and SAEs are reported separately.
|
Day 1 up to end of study (15 days post last administration of study drug)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Dr Etienne VARLAN, Merck Lipha Santé
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Endocrine System Diseases
- Ovarian Cysts
- Cysts
- Ovarian Diseases
- Adnexal Diseases
- Gonadal Disorders
- Polycystic Ovary Syndrome
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Reproductive Control Agents
- Fertility Agents, Female
- Fertility Agents
- Follicle Stimulating Hormone
- Hormones
- Chorionic Gonadotropin
- Cetrorelix
Other Study ID Numbers
- EMR200088-501
- 2007-007932-25 (EudraCT Number)
- INI 28091 (Other Identifier: Merck KGaA)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polycystic Ovarian Syndrome
-
Northwell HealthWithdrawnPolycystic Ovarian Syndrome (PCOS) | Patients Sensitive to Exogenous Gonadotropins | Ovarian Hyper Stimulation Syndrome (OHSS)United States
-
Etlik Zubeyde Hanim Womens' Health and Teaching...CompletedOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome
-
BioromaUnknownOvarian Hyperstimulation Syndrome | Polycystic Ovarian Syndrome | Invitro FertilizationItaly
-
Bruce LesseyTerminatedPolycystic Ovarian SyndromeUnited States
-
Kufa UniversityCompletedPolycystic Ovary SyndromeIraq
-
Duke UniversityTerminatedPolycystic Ovarian SyndromeUnited States
-
V.K.V. American Hospital, IstanbulUnknownPolycystic Ovarian SyndromeTurkey
-
Yunyang Medical CollegeUnknown
-
Ahmed MagedCompletedPolycystic Ovarian Syndrome
-
Mayo ClinicCompletedOverweight | Insulin Resistance | Obese | Polycystic Ovarian Syndrome (PCOS)United States
Clinical Trials on Cetrorelix acetate
-
Northwest Women's and Children's Hospital, Xi'an...Not yet recruiting
-
Assaf-Harofeh Medical CenterRecruiting
-
Università degli Studi 'G. d'Annunzio' Chieti e...Unknown
-
Seoul National University Bundang HospitalCompletedInfertilityKorea, Republic of
-
University of OxfordOxford Fertility Limited, United KingdomUnknown
-
Cairo UniversityCompletedOther Complications Associated With Artificial FertilizationEgypt
-
Bio Genuine (Shanghai) Biotech Co., Ltd.Not yet recruitingAssisted Reproductive Technology | Controlled Ovarian HyperstimulationChina
-
ClinAmygateCairo University; Al-Azhar University; Beni-Suef UniversityCompletedOvarian Hyperstimulation SyndromeEgypt
-
Main Line Fertility CenterFerring PharmaceuticalsCompleted
-
Peking University Third HospitalRecruiting